ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study

Huang, YuHong; Zhu, Teng; Zhang, XiaoLing; Li, Wei; Zheng, XingXing; Cheng, MinYi; Ji, Fei; Zhang, LiuLu; Yang, CiQiu; Wu, ZhiYong*; Ye, GuoLin*; Lin, Ying*; Wang, Kun*佛山市第一人民医院; 广东省人民医院; 南方医科大学; 中山大学; 1; y
ECLINICALMEDICINE2023-4DOI: 10.1016/j.eclinm.2023.101899
14被引6阅读
引用收藏
分享

摘要

Background Accurate identification of pCR to neoadjuvant chemotherapy (NAC) is essential for determining appropriate surgery strategy and guiding resection extent in breast cancer. However, a non-invasive tool to predict pCR accurately is lacking. Our study aims to develop ensemble learning models using longitudinal multiparametric MRI to predict pCR in breast cancer. Methods From July 2015 to December 2021, we collected pre-NAC and post-NAC multiparametric MRI sequences per patient. We then extracted 14,676 radiomics and 4096 deep learning features and calculated additional delta -value features. In the primary cohort (n = 409), the inter-class correlation coefficient test, U-test, Boruta and the least absolute shrinkage and selection operator regression were used to select the most significant features for each subtype of breast cancer. Five machine learning classifiers were then developed to predict pCR accurately for each subtype. The ensemble learning strategy was used to integrate the single-modality models. The diagnostic performances of models were evaluated in the three external cohorts (n = 343, 170 and 340, respectively). Findings A total of 1262 patients with breast cancer from four centers were enrolled in this study, and pCR rates were 10.6% (52/491), 54.3% (323/595) and 37.5% (66/176) in HR+/HER2-, HER2+ and TNBC subtype, respectively. Finally, 20, 15 and 13 features were selected to construct the machine learning models in HR+/HER2-, HER2+ and TNBC subtypes, respectively. The multi-Layer Perception (MLP) yields the best diagnostic performances in all subtypes. For the three subtypes, the stacking model integrating pre-, post-and delta-models yielded the highest AUCs of 0.959, 0.974 and 0.958 in the primary cohort, and AUCs of 0.882-0.908, 0.896-0.929 and 0.837-0.901 in the external validation cohorts, respectively. The stacking model had accuracies of 85.0%-88.9%, sensitivities of 80.0%-86.3%, and specificities of 87.4%-91.5% in the external validation cohorts. Interpretation Our study established a novel tool to predict the responses of breast cancer to NAC and achieve excellent performance. The models could help to determine post-NAC surgery strategy for breast cancer. Funding This study is supported by grants from the National Natural Science Foundation of China (82171898, 82103093), the Deng Feng project of high-level hospital construction (DFJHBF202109), the Guangdong Basic and Applied Basic Research Foundation (grant number, 2020A1515010346, 2022A1515012277), the Science and Technology Planning Project of Guangzhou City (202002030236), the Beijing Medical Award Foundation (YXJL-2020-0941-0758), and the Beijing Science and Technology Innovation Medical Development Foundation (KC2022-ZZ-0091-5). Funding sources were not involved in the study design, data collection, analysis and interpretation, writing of the report, or decision to submit the article for publication. 2023;58: Published 2023 https://doi.org/10. 1016/j.eclinm.2023. 101899

学科与关键词

关键词
Breast cancerMulti-parametric MRINeoadjuvant chemotherapyPathological complete responseLongitudinal radiomicsDeep learning
相关
加载中…
  • Use of Pretreatment Multiparametric MRI to Predict Tumor Regression Pattern to Neoadjuvant Chemotherapy in Breast Cancer
    Liu, Chen; Huang, Xiaomei; Chen, Xiaobo; Shi, Zhenwei; Liu, Chunling; Liang, Yanting; Huang, Xin; Chen, Minglei; Chen, Xin; Liang, Changhong; Liu, Zaiyi*ACADEMIC RADIOLOGY, 2023, 30: S62-S70.
  • MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer
    Shi, Zhenwei; Huang, Xiaomei; Cheng, Ziliang; Xu, Zeyan; Lin, Huan; Liu, Chen; Chen, Xiaobo; Liu, Chunling; Liang, Changhong; Lu, Cheng; Cui, Yanfen; Han, Chu; Qu, Jinrong; Shen, Jun; Liu, Zaiyi*RADIOLOGY, 2023, 308(1): e222830.被引 5
  • Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer
    Zeng, Qiao; Xiong, Fei; Liu, Lan; Zhong, Linhua; Cai, Fengqin; Zeng, Xianjun*ACADEMIC RADIOLOGY, 2023, 30 Suppl 2: S38-S49.
查看全部 →

发表信息

论文状态
公开发表
期刊
ECLINICALMEDICINE
发表日期
2023-04
卷期
第 58 卷
DOI
10.1016/j.eclinm.2023.101899
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82171898, 82103093, DFJHBF202109]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010346, 2021A1515011570, 2022A1515012277]; Guangzhou Science and Technology Project [202002030236, 202102021055]; Beijing Medical Award Foundation [YXJL-2020- 0941-0758]; Beijing Science and Technology Innovation Medical Development Foundation [KC2022-ZZ-0091-5]

作者

  • H

    Huang, YuHong (第一作者)

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhu, Teng

    guangdong prov peoples hosp · southern med univ

查看全部 13 位作者收起作者
  • Z

    Zhang, XiaoLing

    1 · sun yat sen univ

  • L

    Li, Wei

    first peoples hosp foshan

  • Z

    Zheng, XingXing

    guangdong prov peoples hosp · southern med univ

  • C

    Cheng, MinYi

    guangdong prov peoples hosp · southern med univ

  • J

    Ji, Fei

    guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, LiuLu

    guangdong prov peoples hosp · southern med univ

  • Y

    Yang, CiQiu

    guangdong prov peoples hosp · southern med univ

  • W

    Wu, ZhiYong (通讯)

    shantou cent hosp

  • Y

    Ye, GuoLin (通讯)

    first peoples hosp foshan

  • L

    Lin, Ying (通讯)

    1 · sun yat sen univ

  • W

    Wang, Kun (通讯)

    guangdong prov peoples hosp · southern med univ · guangdong prov people hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417